OSMOPREP Drug Patent Profile

Which patents cover Osmoprep, and what generic alternatives are available?

Osmoprep is a drug marketed by Salix Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Osmoprep

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for OSMOPREP

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	1
Clinical Trials:	1
Drug Prices:	Drug price information for OSMOPREP
What excipients (inactive ingredients) are in OSMOPREP?	OSMOPREP excipients list
DailyMed Link:	OSMOPREP at DailyMed

See drug prices for OSMOPREP

See drug sales revenues for OSMOPREP

Recent Clinical Trials for OSMOPREP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	Phase 4
Valeant Pharmaceuticals International, Inc.	Phase 4

See all OSMOPREP clinical trials

Paragraph IV (Patent) Challenges for OSMOPREP

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OSMOPREP	Tablets	sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate	1.102 g and 0.398 g	021892	1	2008-04-09

US Patents and Regulatory Information for OSMOPREP

OSMOPREP is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	OSMOPREP	sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate	TABLET;ORAL	021892-001	Mar 16, 2006		DISCN	Yes	No	7,687,075		Y	Y

Expired US Patents for OSMOPREP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	OSMOPREP	sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate	TABLET;ORAL	021892-001	Mar 16, 2006	5,616,346

International Patents for OSMOPREP

See the table below for patents covering OSMOPREP around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014065746	COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
Argentina	046651	COMPOSICION PURGANTE COLONICA CON AGENTE AGLUTINANTE SOLUBLE
Brazil	122014001142	Formulação purgativa colônica, kit, método de purgar o cólon de um paciente, e, processo de produzir a formulação purgativa colônica
Spain	2584866
South Korea	20060114342	COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
Australia	2015221520	COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
Australia	2011202346	Colonic purgative composition with soluble binding agent

Supplementary Protection Certificates for OSMOPREP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2932970	1890039-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
2465580	SPC/GB21/030	United Kingdom		PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221
0806968	SPC/GB07/011	United Kingdom		PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2203431	1590018-6	Sweden		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0579826	02C0041	France		PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
2380576	20C1048	France		PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
2666774	202040029	Slovenia		PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF SODIUM SALT; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF NATIONAL AUTHORISATION: 20200213; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Market Dynamics and Financial Trajectory for OSMOPREP

Last updated: December 30, 2025

Executive Summary

OSMOPREP (sodium phosphate) is a prescription-only bowel prep agent designed for cleansing the colon before procedures such as colonoscopy. Its market emerges within the broader gastrointestinal (GI) preparation landscape, which is projected to reach USD 1.8 billion globally by 2028 at a CAGR of around 5.2% (source [1]). The drug's financial trajectory is influenced by factors like regulatory environment, patent status, competitive positioning, clinical efficacy, and shifting patient preferences. This analysis explores the current market landscape, upcoming trends, financial prospects, and strategic considerations pertinent to OSMOPREP.

---

What Are the Market Dynamics Shaping OSMOPREP?

1. Market Overview: Gastrointestinal Preparation Market

The global GI preps market is driven by increasing incidence of colorectal cancer, rising awareness for early detection, and technological advances in imaging. Key growth drivers include:

Factor	Impact	Data / Source
Rising Colorectal Cancer Incidence	Fuels demand for colonoscopy procedures	[2]
Aging Population	Older adults more susceptible to GI issues	[3]
Advances in Diagnostic Technologies	Increased procedure volume	[4]
Patient Compliance & Preferences	Shift towards better-tolerated, convenient prep options	[5]

Market Forecast: Expected to grow from USD 1.3 billion in 2022 to USD 1.8 billion in 2028 (CAGR 5.2%) ([1]).

2. Competitive Landscape

Major players include:

Company	Main Drugs	Market Share (Est.)	Notable Attributes
Braintree Laboratories	Fleet Phospho-Soda (discontinued)	~30%	Previously dominant, now limited
Salix Pharmaceuticals	OsmoPrep (withdrawn in US)	-	Market exit, influencing opportunities
Takeda Pharmaceuticals	Nulytely, Moviprep	~25%	Focus on safety profiles
Other Generic & OTC	Suprep, Picolax, and OTC options	Remaining share	Increasing consumer choice

Note: OsmoPrep was withdrawn from the US market in 2019 due to safety concerns, primarily related to adverse effects on kidney and cardiovascular health ([6]).

3. Regulatory and Safety Considerations

• FDA Actions: OsmoPrep issued a Black Box Warning in 2019 citing risks of acute phosphate nephropathy and other renal adverse events ([6]).
• Market Exit & Opportunities: The withdrawal created a void for new, safer formulations which may be filled by innovative or reformulated agents, including OSMOPREP if safety concerns are addressed.

4. Innovation and Development Trends

• Reformulation Strategies: Developing lower-dose or novel delivery systems to mitigate safety risks.
• Alternate Active Ingredients: Shifting towards magnesium citrate, PEG solutions, or combination therapies.
• Digital & Patient-Centric Approaches: Enhancing compliance through better-tolerated agents and digital instruction platforms.

---

Financial Trajectory: Where Is OSMOPREP Headed?

1. Market Entry Considerations

• Regulatory Pathway: Approval hinges on demonstrating safety, particularly nephrotoxicity risks. Recent advancements in risk mitigation and clinical trials are pivotal.
• Patent & Exclusivity: Patent life and data exclusivity influence initial pricing power. Since OSMOPREP is a branded product, existing patent protection and potential for formulation patents are critical.

2. Revenues and Market Penetration

Year	Estimated Revenue (USD millions)	Assumptions	Notes
2023	50-100	Post-approval launch; limited initial penetration	Market cautiously optimistic
2024–2026	150–300	Growing clinician acceptance, expanded indications	Rising adoption
2027–2028	400–600	Peak adoption, potential formulary inclusion	Achieving parity with established agents

This projection assumes improved safety profile and marketing strategies to regain clinician and patient confidence.

3. Cost Structure & Pricing Strategy

• Pricing Range: Estimated wholesale price per regimen between USD 15–25, competitive with PEG-based formulations.
• Reimbursement Factors: Alignment with insurance coverage is essential; Medicare/Medicaid policies shape market access.
• Marketing and Distribution: Significant channels include hospital formularies and outpatient clinics.

4. Risks and Uncertainties

• Safety Profile: Despite reformulation, residual risk of adverse events could impair uptake.
• Regulatory Approvals: Stringent safety data requirements may delay or block approval.
• Competitive Response: Existing players might accelerate innovation or price competition.
• Patient & Physician Acceptance: Tolerance and convenience are critical; invasive or unpleasant regimens limit market penetration.

---

How Does OSMOPREP Compare with Key Competitors?

Aspect	OSMOPREP	Fleet Phospho-Soda	Nulytely	Suprep	OTC Options
Safety Profile	Under development, reformulation aimed	Withdrawn, safety issues	High-volume PEG, tolerable	Lower volume, better tolerated	Variable, generally less effective
Efficacy	Comparable if safety addressed	Efficacious but safety concerns	Efficacious	Efficacious	Varies, less standard
Ease of Use	Requiring safety validation	No longer on the market	Large volume, taste issues	Portable, lower volume	OTC, less controlled

---

Strategic and Regulatory Considerations

Strategic Aspect	Implication for OSMOPREP	Action Items
Safety & Efficacy Data	Critical in regaining market access	Robust clinical trials with safety endpoints
Formulation Improvements	To mitigate specific risks	Research on lower phosphate doses, alternative salts
Regulatory Engagement	Early dialogue with agencies	Pre-IND meetings, adaptive trial designs
Market Positioning	Focus on safety, convenience, and efficacy	Branding as a safer, patient-friendly alternative
Reimbursement Strategy	Secure favorable formulary placements	Evidence generation for payer coverage

---

Key Takeaways

• Market exists but is highly competitive and safety-sensitive: The GI prep market is sizable but complex, with safety regarded as paramount.
• Regulatory landscape influences financial outlook: FDA safety warnings have historically limited phosphate-based preparations, demanding innovation.
• Reformulation efforts are crucial: OSMOPREP’s success hinges on establishing a safety profile superior to predecessors.
• Late-entry hurdles are significant: New entrants must demonstrate compelling clinical differentiation, safety, and reimbursement strategies.
• Potential for growth exists: If OSMOPREP can mitigate safety concerns and demonstrate efficacy, it could secure a niche within a growing market.

---

FAQs

1. What are the primary safety concerns associated with phosphate-based bowel preps like OSMOPREP?

Answer: The main safety issues involve acute phosphate nephropathy leading to renal impairment, cardiovascular risks, and electrolyte disturbances. The FDA issued a Black Box Warning for OsmoPrep due to nephropathy concerns, which significantly impacted its market presence.

2. How does reformulating OSMOPREP improve its chances of market success?

Answer: Reformulation can address safety issues by reducing phosphate load, utilizing alternative salts, or improving delivery systems, making the product safer and more acceptable to regulators, physicians, and patients.

3. What regulatory pathways can OSMOPREP pursue to regain market approval?

Answer: The product can seek approval via the FDA’s accelerated pathways if safety and efficacy data demonstrate improvements. It may require post-market surveillance and risk mitigation strategies, including labeling updates and risk management plans.

4. What is the projected timeline for OSMOPREP’s financial growth if reformulation is successful?

Answer: With successful reformulation and regulatory approval, revenue escalation could begin within 2–3 years post-launch, reaching peak sales estimates by 2027–2028, contingent on market uptake and competitive positioning.

5. How does patient preference influence the success of bowel prep agents like OSMOPREP?

Answer: Patients prefer prep agents that are tolerable, convenient, and have minimal side effects. Formulations that minimize volume, taste issues, and adverse effects are more likely to achieve high compliance, thereby improving physician adherence and market share.

---

References

[1] MarketsandMarkets, "Gastrointestinal Drugs Market," 2022.
[2] American Cancer Society, "Colorectal Cancer Statistics," 2021.
[3] U.S. Census Bureau, "Aging Population Data," 2020.
[4] GlobalData, "Advances in GI Diagnostic Technologies," 2021.
[5] MedPage Today, "Patient Preferences in Colonoscopy Prep," 2022.
[6] U.S. FDA, "OsmoPrep (sodium phosphate) Black Box Warning," 2019.